Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

Jan Philipp Bewersdorf; Amer M. Zeidan

doi:10.18632/oncotarget.27919

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

Jan Philipp Bewersdorf and Amer M. Zeidan _

PDF | Full Text | How to cite

Oncotarget. 2021; 12:1314-1317. https://doi.org/10.18632/oncotarget.27919

Metrics: PDF 1097 views | Full Text 1715 views | ?

Abstract

Jan Philipp Bewersdorf1 and Amer M. Zeidan1^,2

1 Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA

2 Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA

Correspondence to:

Amer M. Zeidan,

email:

[email protected]

Keywords: acute myeloid leukemia; AML; PLK-1 inhibitor; onvansertib; volasertib

Received: February 24, 2021 Accepted: March 08, 2021 Published: June 22, 2021

Copyright: © 2021 Bewersdorf and Zeidan. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27919

Publication Alerts

Research Perspectives:

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia

Abstract